Telangiectasias
5
1
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
40%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias
Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
Treatment of Leg Telangiectasias With Nd:YAG 1064nm